HEALTH experts are alarmed by the invasive meningococcal disease (IMD), with Serogroup B identified as the leading cause, accounting for approximately 68 percent of cases over the years.

the Centers for Disease Control and Prevention estimates that 1000 cases of invasive meningococcal disease (IMD) occurred in the United States, with 130 (13%) case fatalities and an equal rate of ...

and Y strains responsible for most cases of invasive meningococcal disease (IMD) encountered in the US. GSK is currently the market leader in the meningococcal vaccine market, racking up sales of ...

The European Commission (EC) has granted approval for a single-vial, fully liquid presentation of GSK's Menveo vaccine (MenACWY), designed to protect against invasive meningococcal disease (IMD ...

The Meningococcal Vaccine Market has been experiencing significant growth in recent years, driven by increasing awareness about meningococcal disease and the importance of vaccination. According to ...

The majority of invasive meningococcal disease cases in high school students are preventable if national recommendations on meningococcal conjugate vaccine are fully implemented. The results of ...

to help protect against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W and Y. This single-vial presentation is now licenced for active immunisation of children from 2 ...